Nature Medicine: Semaglutide in HFpEF Across Obesity Class and by Body Weight Reduction: a Prespecified Analysis of the STEP-HFpEF Trial

The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing worldwide, and there are few effective treatments. 

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the STEP-HFpEF trial. 

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial. 

Read the full article in Nature Medicine: Semaglutide in HFpEF Across Obesity Class and by Body Weight Reduction: a Prespecified Analysis of the STEP-HFpEF Trial

Related Content

Aug. 26, 2023

Good Morning America: New Study Highlights Benefits to Weight Loss Drugs
Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.
Aug. 26, 2023

CBS Evening News: Study Shows Wegovy May Reduce Risk of Heart Failure
The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.